Nicole Lamanna, MD
On the web
Overview
Nicole Lamanna, MD, is a Clinical Professor of Medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division. Dr. Lamanna is a hematologist/oncologist whose research interests include lymphoid leukemias, specifically chronic lymphocytic leukemia (CLL).
Dr. Lamanna is a pioneering investigator and internationally recognized leader in CLL. As the inaugural incumbent of the Judy Horrigan Professorship of Medicine, she has expanded Columbia’s CLL research efforts, elevated the public profile of the disease, and advanced some of the most promising avenues of research for its treatment. Her work has been widely published in leading peer-reviewed journals, including Blood, The New England Journal of Medicine, The Journal of Clinical Oncology, eJHaem, Blood Advances, and Clinical Lymphoma, Myeloma & Leukemia, shaping both academic research and frontline patient care. She is a frequent invited speaker at major national and international forums, including the American Society of Hematology (ASH), the European Hematology Association (EHA), and the Society of Hematologic Oncology (SOHO), where she presents on targeted therapies, emerging agents, and personalized approaches to CLL treatment. Through her innovative research, clinical expertise, and leadership in clinical trials, Dr. Lamanna has helped redefine CLL as a chronic, manageable condition for many patients. While curative therapy remains a goal, therapies developed through trials she has led at Columbia have significantly improved patient outcomes and life expectancy. A dedicated patient advocate, she is deeply committed to education, access to expert care, and delivering both cutting-edge treatment and compassionate clinical care.
She earned her medical degree from Albert Einstein College of Medicine and completed her fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center
Areas of Expertise / Conditions Treated
- Acute Leukemia
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Acute Myeloid Leukemia
- Chronic Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Lymphoid Leukemia
- Chronic Myelogenous Leukemia
- Essential Thrombocythemia
- Hairy Cell Leukemia
- Hematologic Malignancy
- Hemolytic Anemia
- Immune Thombocytopenic Purpura
- Large Granular Lymphocytic Leukemia
- Myelodysplastic Syndrome
- Myelofibrosis
- Myeloproliferative Disorder
- Polycythemia Vera
- Waldenstrom's Macroglobulinemia
Academic Appointments
- Professor of Medicine at CUMC
Administrative Titles
- Chief of Leukemia Service, Hematologic Malignancies
- Co-Director, Columbia Adult Infusion Center at CUMC
- Academy of Clinical Excellence (ACE), Columbia University
- Chair, Internal Review Board (IRB-4), CUMC
- Financial Conflict of Interest Committee Member at CUMC
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
- NewYork-Presbyterian / Columbia University Irving Medical Center
- NewYork-Presbyterian / Columbia University Irving Medical Center
- NewYork-Presbyterian / Columbia University Irving Medical Center
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Female
Schedule an Appointment
Virtual Visits/Telehealth
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Aetna
- Aetna Signature Administrators
- EPO
- HMO
- Medicare Managed Care
- NY Signature
- POS
- PPO
- Student Health
Affinity Health Plan
- Essential Plan
- Medicaid Managed Care
Amida Care
- Special Needs
Cigna
- EPO
- Great West (National)
- HMO
- POS
- PPO
ElderServe
- Special Needs
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross/Blue Shield
- EPO
- HMO
- Medicare Managed Care
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Individual Network (Exchange)
- Medicaid Managed Care
Fidelis Care
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicaid Managed Care
- Medicare Managed Care
Healthspring (Cigna Medicare)
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
UnitedHealthcare
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Medicare Managed Care
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
- Special Needs
WellCare
- Medicaid Managed Care
- Medicare Managed Care
World Trade Center Health Plan
- World Trade Center Health Plan
Credentials & Experience
Education & Training
- MD, Albert Einstein College Medicine
- Residency: New York University Medical Center
- Fellowship: Memorial Sloan-Kettering Cancer Center
Committees, Societies, Councils
· CLL Society – Medical Advisory Board Member, Co-Chair
· International Workshop of Chronic Lymphocytic Leukemia (iwCLL)
· American Society of Clinical Oncology (ASCO)
· American Society of Hematology (ASH)
· Patient Power – CLL Discussant/Patient Advocacy Meetings
Board Certifications
- Medical Oncology
Honors & Awards
· Academy of Clinical Excellence (ACE) Columbia University
· New York Presbyterian Columbia University Medical Center - Physician of the Year Award
· Castle Connolly Exceptional Women in Medicine
· New York Magazine “Best Doctors”
· Castle Connolly America’s Top Doctors
· Castle Connolly Top Doctors: New York Metro Area
· Castle Connolly America’s Top Doctors for Cancer
· Memorial Sloan-Kettering Society Award: activated pathways in CLL
· Memorial Sloan-Kettering Resident Hematology Attending Teaching Award
· Mortimer Lacher (Lymphoma) Fellowship Award
· American Society of Clinical Oncology Merit Award
Research
As we work to establish an improved standard of care for CLL, our goal is to maximize impact while minimizing side effects. This can be a challenge – chemotherapy drugs previously considered the standard of care caused significant side effects, and were so poorly tolerated by patients, that continued use proved unsustainable. We have been successful in lessening these patients’ burden of disease with novel targeted therapies, which are now the new standard of care in treating patients with CLL (i.e. Bruton tyrosine kinase inhibitors and B-cell lymphoma 2 inhibitors).
Building on transformational advances, we have been driving forward a robust clinical research agenda to further refine therapeutic precision and broaden effective options for patients with CLL. At Columbia University, we offer an array of clinical trials from exploring next-generation targeted approaches to investigating emerging bispecific antibodies and therapies for relapsed refractory and Richter’s transformation. For a complete list of open clinical trials, please visit our Clinical Trials.
Related News
- April 25, 2025
Topic
